Company intelligence / Profile preview

Serenity Pharmaceuticals

Miami, Florida, United Statess2.q4cdn.com ↗

Ownership: Private
Development stage: Other

Overview

Noctiva (desmopressin acetate) nasal spray was FDA-approved for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It was the first FDA-approved therapy for this indication. The product and global rights were acquired by Acerus Pharmaceuticals in March 2022.

Therapeutic areas: Nephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Serenity Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serenity Pharmaceuticals.

Explore the full profile